TNBC

News

Datroway is first TROP2 drug for frontline breast cancer

AZ and Daiichi's Datroway has been cleared by the FDA as first-line treatment for triple-negative breast cancer patients ineligible for immunotherapy.

News

AstraZeneca and Daiichi Sankyo logos next to Datroway box

Datroway filed for TNBC in EU after data delay

Daiichi Sankyo and AstraZeneca have filed their first marketing application for TROP2-targeting Datroway in triple-negative breast cancer.

Events

Partner Content

Triple Negative Breast Cancer Drug Development Digital Summi...

Fast-track the Discovery & Development of TNBC

Datroway is first TROP2 drug for frontline breast cancer

Datroway filed for TNBC in EU after data delay

Triple Negative Breast Cancer Drug Development Digital Summi...

Ipsen charts $1.75bn course for Kartos acquisition

Discover a new era of healthcare panel engagement: Grounded ...

Editor's Picks